SCHEMBL23329183

SCHEMBL23329183

CC1CC2(O)CCCC(NC(=O)c3cc(-c4cncs4)cc4c3ccn4SF)(C1)C2

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CD38 P28907 8/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23329867 0.78 CD38 (0.52) CD38
SCHEMBL23329393 0.72 CD38 (0.47) CD38
SCHEMBL23329181 0.69 CD38 (0.43) CD38
SCHEMBL23329531 0.68 HDAC4 (0.42) CD38
SCHEMBL23329330 0.68 CD38 (0.44) CD38
SCHEMBL23329198 0.67 CD38 (0.38) CD38
SCHEMBL23305459 0.66 CD38 (0.46) CD38
SCHEMBL23329085 0.65 CD38 (0.59) CD38
SCHEMBL23329148 0.64 CD38 (0.60) CD38
SCHEMBL23329533 0.63 CD38 (0.73) CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021087087-A1 N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS MITOBRIDGE INC. (US) 2021-05-06 — — WO disclosed
Send feedback